Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Sathekge

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Theranostics|March 17, 2025
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysisGaia Ninatti, Pietro Scilipoti, Cristiano Pini, et al.
Advances in Radiation Oncology|June 27, 2025
Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin StudyGiuseppe Cardaci, Siddhartha Baxi, Saima Vohra, et al.
Nuclear Medicine Communications|December 20, 2017
68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective studyThabo Lengana, Christophe van de Wiele, Ismaheel Lawal, et al.
Frontiers in Oncology|December 3, 2025
The implication of aberrant NRF2 activation in management of female cancersMankgopo Kgatle, Saidon Mbambara, Olalekan Fadebi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 18, 2012
Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trialAndrei Iagaru, Erik Mittra, Camila Mosci, et al.
Analytical Chemistry|February 15, 2017
In Vitro Functional Quality Characterization of NOTA-Modified SomatropinsNathalie Bracke, Han Yao, Evelien Wynendaele, et al.
Molecular Imaging and Biology|December 8, 2023
The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [<sup>99m</sup>Tc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [<sup>99m</sup>Tc]Tc-EDDA/HYNIC-iPSMA in Prostate CancerEduards Mamlins, Lara Scharbert, Jens Cardinale, et al.
Seminars in Nuclear Medicine|October 8, 2025
Advances in Dosimetry and Imaging for <sup>203</sup>Pb and <sup>212</sup>Pb RadiotheranosticsKeamogetswe Ramonaheng, Milani Qebetu, Kaluzi Banda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Rechallenge and Extended [<sup>177</sup>Lu]Lu-PSMA Therapy in Metastatic Prostate CancerSeyed Ali Mirshahvalad, Amir Iravani, Wolfgang P Fendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 2, 2023
<sup>225</sup>Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findingsMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Theranostics|March 17, 2025
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysisGaia Ninatti, Pietro Scilipoti, Cristiano Pini, et al.
Advances in Radiation Oncology|June 27, 2025
Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin StudyGiuseppe Cardaci, Siddhartha Baxi, Saima Vohra, et al.
Nuclear Medicine Communications|December 20, 2017
68Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective studyThabo Lengana, Christophe van de Wiele, Ismaheel Lawal, et al.
Frontiers in Oncology|December 3, 2025
The implication of aberrant NRF2 activation in management of female cancersMankgopo Kgatle, Saidon Mbambara, Olalekan Fadebi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 18, 2012
Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trialAndrei Iagaru, Erik Mittra, Camila Mosci, et al.
Analytical Chemistry|February 15, 2017
In Vitro Functional Quality Characterization of NOTA-Modified SomatropinsNathalie Bracke, Han Yao, Evelien Wynendaele, et al.
Molecular Imaging and Biology|December 8, 2023
The Theranostic Optimization of PSMA-GCK01 Does Not Compromise the Imaging Characteristics of [<sup>99m</sup>Tc]Tc-PSMA-GCK01 Compared to Dedicated Diagnostic [<sup>99m</sup>Tc]Tc-EDDA/HYNIC-iPSMA in Prostate CancerEduards Mamlins, Lara Scharbert, Jens Cardinale, et al.
Seminars in Nuclear Medicine|October 8, 2025
Advances in Dosimetry and Imaging for <sup>203</sup>Pb and <sup>212</sup>Pb RadiotheranosticsKeamogetswe Ramonaheng, Milani Qebetu, Kaluzi Banda, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 6, 2025
Rechallenge and Extended [<sup>177</sup>Lu]Lu-PSMA Therapy in Metastatic Prostate CancerSeyed Ali Mirshahvalad, Amir Iravani, Wolfgang P Fendler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 2, 2023
<sup>225</sup>Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findingsMike Sathekge, Frank Bruchertseifer, Mariza Vorster, et al.
Pageof 13